Abstract
In the footsteps of groundbreaking achievements made by biomedical research, another scientific revolution is unfolding. Systems biology draws from the chaos and complexity theory and applies computational models to predict emerging behavior of the interactions between genes, gene products, and environmental factors. Adaptation of systems biology to translational and clinical sciences has been termed network medicine and is likely to change the way we think about preventing, predicting, diagnosing, and treating complex human diseases. Network medicine finds gene-disease associations by analyzing the unparalleled digital information discovered and created by high-throughput technologies (dubbed as 'omics' science) and links genetic variance to clinical disease phenotypes through intermediate organizational levels of life such as the epigenome, transcriptome, proteome, and metabolome. Supported by large reference databases, unprecedented data storage capacity, and innovative computational analysis, network medicine is poised to find links between conditions that were thought to be distinct, uncover shared disease mechanisms and key drivers of the pathogenesis, predict individual disease outcomes and trajectories, identify novel therapeutic applications, and help avoid off-target and undesirable drug effects. Recent advances indicate that these perspectives are increasingly within our reach for understanding and managing complex diseases of the digestive system. Ever wondered why it is so difficult to recall a 'textbook case' of a patient with inflammatory bowel disease (IBD) or nonalcoholic fatty liver disease (NAFLD)? It is because while some disorders have distinct etiology and predictable outcomes, IBD and NAFLD cannot be attributed to a single cause and their course varies from being a minor dysfunction to an occasionally life-threatening illness 1, 2 (Figure 1a) . These conditions are determined by interactions between multitudes of genes, gene products, and environmental factors (Figure 1b) . In other words, complex diseases are the byproducts of biological systems in which a large number of intrinsically or extrinsically perturbed constituents interact in nonlinear or chaotic ways, span across successive levels of organization, and show emergence (i.e., system properties cannot be explained or predicted from knowing the parts) 3 . As a result, complex diseases often pose diagnostic challenges, defy prognostication, and require a wide repertoire of (often suboptimal) therapeutic interventions 1, 2 .
Although biomedical research has provided a wealth of information in the past century, it has not resolved the issue of complexity and another revolution was necessary to begin the process of organizing and analyzing data in an entirely new way. Systems biology is a rapidly evolving field that focuses on the complex interactions between biological components and applies mathematical and computational models to predict emerging behavior [4] [5] [6] . Adaptation of this approach to translational and clinical sciences has been termed network medicine 7 . This new discipline aims to improve our understanding of complex diseases, including those of the digestive system, marking the beginning of systems gastroenterology and systems hepatology. between two groups of individuals (usually diseased subjects and healthy controls) 8 .
Identification of allelic polymorphism near the IL28B gene predicting therapeutic responsiveness in chronic hepatitis C was an important example for the utility of GWA approach [9] [10] [11] . Next generation sequencing (parallel sequencing followed by reassembly of genomic DNA fragments) has recently made genomic analysis extremely fast and affordable, permitting whole genome sequencing and generating digital information at an extraordinary pace 5, 12 . DNA microarrays quantify gene expression simultaneously for hundreds of genes and correlate the findings with clinical characteristics such as tumor progression, recurrence, and drug response 13 . The search for disease-associated genes is narrowed by computational methods of prioritization such as gene set enrichment analysis to identify candidate genes at the top or the bottom of all examined genes ranked by expression relative to a reference microarray or published database 14 .
Further complexity results from epigenetic variability (e.g., histone acetylation and DNA methylation), post-translational protein modification, and a large number of regulatory metabolites that account for intermediate molecular phenotypes and link genetic risk variants to clinically manifest disease 12, 15 . These post-genomic organizational scales are analyzed by additional high-throughput methodologies, including liquid chromatography, mass spectrometry, and proton MR spectrometry (Figure 2a ).
Storing and organizing biomedical information amassed by these methods is another fundamental task that must be undertaken to realize the vision of systems biology. The scale and quality of data require high-power computational tools to model and understand complex system behavior in health and disease 16 . After the introduction of terabytes, petabytes, and exabytes, digital information created this way is soon to be measured in zettabytes (ZB), denoting one sextillion or 10 21 bytes. 20 .
Network-based analysis of complex diseases: mapping the interactions
Once components of a biological system are identified, the next step is to analyze their interactions and understand their emerging role in the development of complex diseases.
The mathematical graph (network) theory is a convenient framework for visualizing and interpreting the structural and functional relationships between genes, gene products, and environmental factors 7 . In simplest terms, networks consist of nodes connected with links and arranged in a particular physical layout (topology). Nodes in biological networks can be genes, coding and non-coding RNAs, proteins, metabolites, cells, individuals, diseases, drugs, and so on. Links represent a variety of relationships between these nodes: genes regulated by the same microRNA, proteins associated with the same disease, metabolites involved in the same pathway, individuals exhibiting the same clinical symptoms, and drugs used to treat the same diseases or causing the same adverse reactions.
Networks can be described by scientific formulas and modeled by mechanical circuitries to simulate real-life situations in biological systems 21, 22 . Biological networks commonly follow a scale-free topology in which most nodes have limited connections, while a few nodes (hubs) have a progressively high number of links 23 . Modules in scale-free networks represent clusters of highly interconnected nodes with similar or sequentially arranged functions (e.g., metabolic pathways or signaling cascades) 24 .
Networks can be created by using curated databases, computational predictions, or systematic experimental strategies 6 (Figure 2b) . A key assumption in these studies is that groups of nodes (e.g., genes, miRNAs, proteins, and metabolites) associated with a specific disorder represent a disease module and additional, unknown disease cancer, pointing to this transition as a critical step in hepatocarcinogenesis 28 .
To find biomarkers that predict the clinical behavior of HCC more reliably, Zhang et al.
conducted computational data mining from 3 published sets of microarray analysis on HCC and corresponding normal liver tissue 29 . Networks created from up-regulated and down-regulated genes common to all 3 sets were analyzed to identify hub genes as candidate markers. These hub genes encode key oncogenic signaling pathways (e.g.,
EGFR, FOS, MAPK, and SMAD2) and their use in the HCC classifier improves
predictive accuracy 29 . This study argues for the utility of combining topological features with gene co-expression data to find successful biomarkers and reminds us that high connectivity genes are not necessarily expressed at high levels.
Network-based approaches to find opportunities for drug repositioning, (i.e., identifying new molecular targets for existing drugs by computational methods) is a cost-saving strategy for drug discovery 30 . Dudley et al. compared gene expression signatures of IBD against reference mRNA expression data of cultured cells exposed to 164 drug compounds in the Connectivity Map, a publicly available compendium of drug-gene associations 31 . Drugs were scored based on the degree of discordance between diseaseaffected and drug-affected gene expression patterns to infer potential therapeutic indications. By following this strategy, the anticonvulsant topiramate was identified as a 'repurposed' drug for IBD and its efficacy was experimentally verified in TNBS-induced colitis, illustrating the promise of computational drug repositioning through systems pharmacology 31 .
The utility of creating networks by using arbitrary free-text resources has recently been demonstrated by Sookoian et al., who have set out to find molecular mechanisms shared between alcoholic and nonalcoholic fatty liver disease 32 . The authors searched for cooccurrences of genes and proteins in PubMed abstracts and used computational gene prioritization (ranking based on similarity scores of known genes involved in these conditions) to create functional molecular maps for shared disease pathways. This entirely in silico analysis concluded that insulin signaling is impaired in both conditions, but only NAFLD is linked to cardiovascular disease. Moreover, both conditions are strongly associated with cancer-related pathways, indicating that fatty liver, regardless of the cause, is an emerging mechanism of oncogenic activation 32 .
Conclusions
Rooted in the mathematical graph theory and supported by the philosophy of chaos and complexity, network medicine may seem at first a challenging and intimidating concept.
However, this rapidly evolving field holds a number or promises and is likely to change the way we think about preventing, predicting, diagnosing, and treating human disease.
As in other fields of network medicine, systems gastroenterology is poised to find links between conditions that were thought to be distinct, uncover common underlying disease mechanisms and key drivers of the pathogenesis, predict individual disease outcomes and trajectories, identify novel therapeutic applications, and help avoid off-target and undesirable drug effects. 
